

**REMARKS**

The examiner considers this application to contain two inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1, and requires restriction to either Group I (claims 1-21 and 28-30) or Group II (claims 22-25).

Applicant elects Group I, comprising claims 1-21 and 28-30 and drawn to a method for attenuating the virulence of a microbial pathogen and a method for inhibiting microbial colonization and biofilm formation, with traverse. Traversal is based on the fact that the composition containing c-di-GMP at page 5472, right column of Mayer et al., under "Materials and Methods" is merely a composition used in purifying cellulose synthase from bacterial cell and membrane components ruptured by a French press. Such a composition is not a pharmaceutical composition and could not be used as a pharmaceutical composition because it is neither sterile nor sufficiently purified from other contaminating bacterial components.

Reconsideration and withdrawal of the restriction requirement is respectfully requested.

Appln. No. 10/565,591  
Response dated January 14, 2008  
Reply to Office action of December 13, 2007

Favorable consideration and early allowance are  
hereby respectfully solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant(s)

By /ACY/  
Allen C. Yun  
Registration No. 37,971

ACY:pp  
Telephone No.: (202) 628-5197  
Facsimile No.: (202) 737-3528  
G:\BN\K\karb\karaolis1a\Pto\2008-01-14response.doc